Agios Q4 net loss $108M; AQVESME approved for thalassemia, U.S. launch started

AGIOS PHARMACEUTICALS, INC.

2025-FY EPS reported -$7.12 revenue$54,028,000

PYRUKYND worldwide net revenue $20M in Q4 ($16M U.S., $4M ex-U.S.), up 49% YoY in U.S.
Full-year 2025 PYRUKYND revenue $54M; net loss $108M in Q4 vs $96.5M in Q4 2024.
FDA approved AQVESME (mitapivat) for thalassemia in Dec 2025; U.S. launch began late Jan 2026.
Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026.
Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline data in H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.